These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 31369140)

  • 1. Opioids and Pharmacy: PMP Extension Granted.
    Berlin J
    Tex Med; 2019 Aug; 115(8):22. PubMed ID: 31369140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioid Prescriptions by Specialty in Ohio, 2010-2014.
    Weiner SG; Baker O; Rodgers AF; Garner C; Nelson LS; Kreiner PW; Schuur JD
    Pain Med; 2018 May; 19(5):978-989. PubMed ID: 28339965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mismatch Game: PMP Errors Could Harm Patient-Physician Relationship.
    Berlin J
    Tex Med; 2020 Oct; 116(10):38-39. PubMed ID: 33126269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a Statewide Controlled-Substance Monitoring Requirement on the Opioid Prescribing Practice for Treatment of Acute Pain.
    Derleth BM; Dexter DD; Arndt R; Lea CM; Dierkhising RA; Dow JF
    WMJ; 2020 Mar; 119(1):33-36. PubMed ID: 32348069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioid Prescribing Laws Are Not Associated with Short-term Declines in Prescription Opioid Distribution.
    Davis CS; Piper BJ; Gertner AK; Rotter JS
    Pain Med; 2020 Mar; 21(3):532-537. PubMed ID: 31365095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of State Regulations on Initial Opioid Prescribing Behavior in Rhode Island.
    Barre L; Oliver B; Alexander-Scott N; McCormick M; Elmaleh R; McDonald JV
    R I Med J (2013); 2019 Aug; 102(6):24-26. PubMed ID: 31398964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How does use of a prescription monitoring program change pharmacy practice?
    Green TC; Mann MR; Bowman SE; Zaller N; Soto X; Gadea J; Cordy C; Kelly P; Friedmann PD
    J Am Pharm Assoc (2003); 2013; 53(3):273-81. PubMed ID: 23699676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of mandatory prescription drug monitoring program (PDMP) use laws on prescriber registration and use and on risky prescribing.
    Strickler GK; Zhang K; Halpin JF; Bohnert ASB; Baldwin GT; Kreiner PW
    Drug Alcohol Depend; 2019 Jun; 199():1-9. PubMed ID: 30954863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a health communication campaign to promote the Texas prescription monitoring program.
    Mackert M; Pounders K; Brown LE; Kirtz S; Wagner JH; Ring D; Hill L; Wilcox G; Murthy D; Tierney W; Innerarity S; McGlone M; Holleran Steiker LK; DeSalvo K; Bernhardt JM; Pretorius K
    Health Mark Q; 2020; 37(3):222-231. PubMed ID: 32790502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physician attitudes and experiences with Maryland's prescription drug monitoring program (PDMP).
    Lin DH; Lucas E; Murimi IB; Jackson K; Baier M; Frattaroli S; Gielen AC; Moyo P; Simoni-Wastila L; Alexander GC
    Addiction; 2017 Feb; 112(2):311-319. PubMed ID: 27658522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescription Opioid Misuse and Overuse in the U.S.
    Fleming DA
    Mo Med; 2018; 115(3):189-190. PubMed ID: 30228715
    [No Abstract]   [Full Text] [Related]  

  • 12. Trends in Florida's Prescription Drug Monitoring Program registration and utilization: Implications for increasing voluntary use.
    Delcher C; Wang Y; Young HW; Goldberger BA; Schmidt S; Reisfield GM
    J Opioid Manag; 2017; 13(5):283-289. PubMed ID: 29199394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of a prescription drug monitoring program use mandate on potentially problematic patterns of opioid analgesic prescriptions in New York City.
    Bachhuber MA; Tuazon E; Nolan ML; Kunins HV; Paone D
    Pharmacoepidemiol Drug Saf; 2019 May; 28(5):734-739. PubMed ID: 30920062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescription Drug Monitoring Programs: Relationships Among Program Awareness, Use, and State Mandates.
    Williams KS; Magalotti S; Schrouder K; Knox M; Feldman L; Ujwal D; Lynch D
    J Pain Palliat Care Pharmacother; 2018; 32(2-3):129-133. PubMed ID: 30198819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with the use of the prescription monitoring program by prescribers and pharmacists in Texas.
    Thornton JD; Varisco TJ; Downs CG
    Pharmacoepidemiol Drug Saf; 2021 Apr; 30(4):492-503. PubMed ID: 33458926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescription drug monitoring programs in Australia: A call for a comprehensive evaluation.
    Picco L; Ritter A; Nielsen S
    Drug Alcohol Rev; 2023 May; 42(4):745-747. PubMed ID: 37014802
    [No Abstract]   [Full Text] [Related]  

  • 17. Feeling the pain.
    Nuzback K
    Tex Med; 2015 Jan; 111(1):37-41. PubMed ID: 25624026
    [No Abstract]   [Full Text] [Related]  

  • 18. Covering the Prescription Drug Monitoring Program Gap: Using Shared Decision Making to Reduce Dental Opioid Prescriptions.
    Wang TT; Hersh EV; Panchal N
    J Oral Maxillofac Surg; 2019 Jan; 77(1):7-8. PubMed ID: 30216751
    [No Abstract]   [Full Text] [Related]  

  • 19. Policies to mitigate nonmedical use of prescription medications: how should emerging evidence of gabapentin misuse be addressed?
    Peckham AM; Fairman KA; Sclar DA
    Expert Opin Drug Saf; 2018 May; 17(5):519-523. PubMed ID: 28985090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug Debacle.
    Sorrel AL
    Tex Med; 2016 Jul; 112(7):24-32. PubMed ID: 27441421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.